Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

ClinicalTrials.gov ID: NCT04250337

Public ClinicalTrials.gov record NCT04250337. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, double-blind, placebo-controlled, parallel-group study which is 16 weeks in duration. The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.

Study identification

NCT ID
NCT04250337
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
228 participants

Conditions and interventions

Interventions

Biological · Other

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 2, 2020
Primary completion
Aug 10, 2021
Completion
Sep 15, 2021
Last update posted
May 8, 2022

2020 – 2021

United States locations

U.S. sites
43
U.S. states
18
U.S. cities
35
Facility City State ZIP Site status
Investigate MD Scottsdale Arizona 85255
Orange County Research Institute Anaheim California 92801
Bakersfield Dermatology and Skin Cancer Medical Group Bakersfield California 93309
Wallace Medical Group, Inc. Beverly Hills California 90211
First OC Dermatology Fountain Valley California 92708
Center For Dermatology Clinical Research, Inc. Fremont California 94538
California Allergy and Asthma Medical Group + Research Center Los Angeles California 90025
Keck School of Medicine University of Southern California Los Angeles California 90033
Dermatology Research Associates Los Angeles California 90045
LA Universal Research Center, INC Los Angeles California 90057
ACRC Studies San Diego California 92119
University Clinical Trials, Inc. San Diego California 92123
Southern California Dermatology, Inc. Santa Ana California 92701
Foxhall Dermatology Washington D.C. District of Columbia 20016
St. Francis Medical Institute Clearwater Florida 33765
University of Florida - Gainesville Gainesville Florida 32606
Direct Helpers Medical Center Hialeah Florida 33012
The Community Research of South Florida Hialeah Florida 33016
GSI Clinical Research, LLC Margate Florida 33063
Vitae Research Center, LLC Miami Florida 33135
Well Pharma Medical Research Corp. Miami Florida 33143
ForCare Clinical Research Tampa Florida 33613-1244
Advanced Medical Research Sandy Springs Georgia 30328
The Indiana Clinical Trials Center Plainfield Indiana 46168
Dermatology and Skin Cancer Specialists Rockville Maryland 20850
ActivMed Practices and Research Beverly Massachusetts 01915
Beacon Clinical Research LLC Quincy Massachusetts 02169
Fivenson Dermatology Ann Arbor Michigan 48103
Clarkston Skin Research Clarkston Michigan 48346
MediSearch Clinical Trials Saint Joseph Missouri 64506
ALLCUTIS Research Portsmouth New Hampshire 03801
Psoriasis Treatment Center of Central New Jersey East Windsor New Jersey 08520
Sadick Research Group New York New York 10075
OnSite Clinical Solutions Charlotte North Carolina 28277
Wilmington Dermatology Center Wilmington North Carolina 28405
Clinical Research Institute Medford Oregon 97504
Oregon Dermatology and Research Center Portland Oregon 97210
Oregon Medical Research Center Portland Oregon 97223
OHSU Center for Health and Healing Portland Oregon 97239
Clinical Partners, LLC Johnston Rhode Island 02919
Clinical Research Center of the Carolinas Charleston South Carolina 29407
Arlington Research Center, Inc Arlington Texas 76011
Dermatology Treatment and Research Center Dallas Texas 75230

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04250337, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 8, 2022 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04250337 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →